AirXpanders has treated the first mastectomy patient undergoing breast reconstruction in the AirXpanders patient activated controlled tissue expander system for breast reconstruction (XPAND) trial, using its AeroForm breast tissue expansion device.

The AeroForm tissue expander system features a self-contained tissue expander and a small hand-held wireless remote control.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The prospective randomised controlled open-label pivotal XPAND study will compare the outcomes of tissue expansion of the traditional saline expansion method to the investigational AeroForm, remote-controlled, needle-free tissue expander.

An earlier feasibility trial in Australia showed that the average expansion time associated with the AeroForm remote-controlled tissue expander was 15 days, a fraction of the time required using traditional saline expanders.

Principal investigator of the XPAND trial Leroy Young said the earlier PACE feasibility trial reported that the AeroForm device had the ability to provide breast cancer patients a needle-free and convenient tissue expansion process as part of breast reconstruction following a mastectomy.

"This study will compare the patient-controlled, carbon-dioxide-based AeroForm device with the standard saline injection method, an often arduous process that has historically been a major deciding factor against breast reconstruction for many women," Young added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said enrolment of patients would continue until a total of 92 AeroForm devices and 46 saline expanders have been implanted in patients.